Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 3
Submit an article Journal homepage
199
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Hemoglobin is a key determinant of quality of life before and during azacitidine-based therapy for myelodysplasia and low blast count acute myeloid leukemia

Zoe K. McQuiltena Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia;b Department of Haematology, Monash Health, Melbourne, AustraliaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9698-7185View further author information
ORCID Icon,
Ljoudmila Busijaa Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, AustraliaView further author information
,
John F. Seymourc Department of Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Australia;d Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, AustraliaORCID Iconhttps://orcid.org/0000-0003-2188-6835View further author information
ORCID Icon,
Simon Stanworthe Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK;f Clinical Department, NHS Blood and Transplant, Oxford, UK;g Radcliffe Department of Medicine, University of Oxford, and NIHR Oxford Biomedical Research Centre, Oxford, UKView further author information
,
Erica M. Wooda Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia;b Department of Haematology, Monash Health, Melbourne, AustraliaORCID Iconhttps://orcid.org/0000-0001-7527-2340View further author information
ORCID Icon,
Melita Kenealyh Cabrini Health, Melbourne, Australia;i Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, AustraliaView further author information
,
Robert Weinkovej Wellington Blood & Cancer Centre, Capital & Coast District Health Board, Wellington, New Zealand;k Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand;l Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New ZealandORCID Iconhttps://orcid.org/0000-0003-3645-7988View further author information
ORCID Icon & on behalf of the Australasian Leukaemia and Lymphoma Group (ALLG) show all
Pages 676-683 | Received 23 Jul 2021, Accepted 23 Nov 2021, Published online: 17 Dec 2021

References

  • Stauder R, Yu G, Koinig KA, et al. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia. 2018;32(6):1380–1392.
  • Jansen AJ, Essink-Bot ML, Beckers EA, et al. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol. 2003;121(2):270–274.
  • Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594–7603.
  • McQuilten ZK, Polizzotto MN, Wood EM, et al. Myelodysplastic syndrome incidence, transfusion dependence, health care use, and complications: an Australian population-based study 1998 to 2008. Transfusion. 2013;53(8):1714–1721.
  • McQuilten ZK, Sundararajan V, Andrianopoulos N, et al. Monosomal karyotype predicts inferior survival independently of a complex karyotype in patients with myelodysplastic syndromes. Cancer. 2015;121(17):2892–2899.
  • Szende A, Schaefer C, Goss TF, et al. Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health Qual Life Outcomes. 2009;7(1):81.
  • Spiriti MA, Latagliata R, Niscola P, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol. 2005;84(3):167–176.
  • Pinchon DJ, Stanworth SJ, Doree C, et al. Quality of life and use of red cell transfusion in patients with myelodysplastic syndromes. A systematic review. Am J Hematol. 2009;84(10):671–677.
  • de Swart L, Smith A, Fenaux P, et al. Management of 1000 patients with low- and intermediate-1 risk myelodypslastic syndromes in the European LeukemiaNet MDS registry. Leukemia Research. 2011;35:S3.
  • Mo A, McQuilten ZK, Wood EM, et al. Red cell transfusion thresholds in myelodysplastic syndromes: a clinician survey to inform future clinical trials. Intern Med J. 2017;47(6):695–698.
  • Stanworth SJ, Killick S, McQuilten ZK, REDDS Investigators, et al. Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. Br J Haematol. 2020;189(2):279–290.
  • Efficace F, Gaidano G, Breccia M, et al. Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. Br J Haematol. 2015;168(3):361–370.
  • Kenealy M, Patton N, Filshie R, et al. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). Leuk Lymphoma. 2017;58(2):298–307.
  • Kenealy M, Hertzberg M, Benson W, et al. Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia. Haematologica. 2019;104(4):700–709.
  • Meredith W, Tisak J. Latent curve analysis. Psychometrika. 1990;55(1):107–122.
  • McArdle JJ. Dynamic but structural equation modelling of repeated measures data. In: Cattell RB, Nesselroade J, editors. Handbook of multivariate experimental psychology. 2 ed. New York: Plenum Press; 1988. p 561–614.
  • Carson JL, Carless PA, Hebert PC. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2012;4:CD002042.
  • University LC. Impact of 2 transfusion strategies on quality of life of multitransfused patients with low-risk myelodysplastic syndrome (SMD-transfu) ClinicalTrials.gov reference NCT03643042. 2018.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.